Record Futures Volumes, Strategic Partnership Agreements, Scrip Dividend, Technical Updates, and Product Launch - Research Reports on ICE, BNY Mellon, HSBC, Cummins and Honeywell

NEW YORK, September 1, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Intercontinental Exchange, Inc. (NYSE: ICE), The Bank of New York Mellon Corporation (NYSE: BK), HSBC Holdings plc (NYSE: HSBC), Cummins Inc. (NYSE: CMI) and Honeywell International Inc. (NYSE: HON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6105-100free.

--
Intercontinental Exchange, Inc. Research Reports
On August 27, 2014, Intercontinental Exchange, Inc. (ICE) announced that Liffe Long Gilt futures and Ultra Long Gilt futures have set a new daily volume record with 1,042,074 contracts and 5,118 contracts traded respectively on August 26, 2014. The previous daily volume record for Long Gilt futures was 905,515 contracts set on May 27, 2014; and for Ultra Long Gilt futures, the previous daily volume record was set on May 28, 2014 at 4,702 contracts. The full research reports on ICE are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/ICE/report.pdf

--
The Bank of New York Mellon Corporation Research Reports
On August 27, 2014, The Bank of New York Mellon Corporation (BNY Mellon) reported that it has signed a trade processing partnership with Helaba (Landesbank Hessen-Thuringen) and the G25, a group representing the 25 largest Sparkassen in Germany. The Company stated that the new partnership will help boost trade between the German Mittelstand and the Asia-Pacific region (APAC). BNY Mellon will promote Helaba and G25 group brands in APAC via its correspondent banking network, and in return, Helaba and the Sparkassen will route letters of credit from German importers via BNY Mellon's branch network. Commenting on the partnerships, Ian Stewart, CEO, Treasury Services at BNY Mellon stated, "This deal helps connect the famed Mittelstand with the fastest growing region in the world." The full research reports on BNY Mellon are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/BK/report.pdf

--
HSBC Holdings plc Research Reports
On August 28, 2014, HSBC Holdings plc (HSBC) announced that the Market Value for the issue of new shares under the scrip dividend alternative for Q2 2014 has been fixed at $10.6850 per new share. According to HSBC, this Market Value is the US dollar equivalent of £6.4478 being the average of the middle market quotations for the ordinary shares on the London Stock Exchange as derived from the Daily Official List for the five business days beginning on August 20, 2014. HSBC had declared its Q2 2014 interim dividend of $0.10 per ordinary share on August 4, 2014, payable in cash in US dollars, sterling or Hong Kong dollars, or a combination of these currencies, with a scrip dividend alternative. The full research reports on HSBC are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/HSBC/report.pdf

--
Cummins Inc. Research Reports
On August 27, 2014, the stock of Cummins Inc. (Cummins) ended at $145.19, representing a gain of 0.71% from the previous day's closing. Shares in Cummins opened the session at $144.68, and fluctuated in the range of $144.40 - $145.37, with a total of 0.86 million shares changing hands. The stock has witnessed a decline of 0.11% in last one month, compared to the Dow Jones Industrial Average which rose 0.82% during the same period. The full research reports on Cummins are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/CMI/report.pdf

--
Honeywell International Inc. Research Reports
On August 26, 2014, UOP LLC (UOP), a wholly owned subsidiary of Honeywell International Inc. (Honeywell), announced the commercial launch of an integrated bioreactor system to efficiently remove organic and inorganic contaminants from a wide range of industrial wastewater streams. Based on Honeywell's immobilized cell bioreactor technology, the UOP XCeed™ bioreactor system helps industrial, manufacturing, and groundwater remediation facilities meet contaminant removal specifications for wastewater discharge or reuse. "Using our expertise in process development, we have designed a high-performance biological treatment system that meets requirements efficiently and cost-effectively. UOP is using 100 years of experience purifying various process streams to create superior contaminant removal solutions," said Mike Millard, Senior Vice President and General Manager of Honeywell's UOP Catalysts, Adsorbents and Specialties business. The full research reports on Honeywell are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/HON/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

SOURCE Analysts Review